{"id":"no-anticholinergic-deprescription","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anticholinergic deprescribing is a clinical intervention aimed at reducing exposure to anticholinergic drugs, which are associated with cognitive impairment, falls, and other adverse effects particularly in older adults. By systematically identifying and discontinuing unnecessary anticholinergic medications, this approach seeks to improve patient safety and reduce medication burden. This is a practice guideline or clinical protocol rather than a pharmacological agent.","oneSentence":"This is a deprescribing strategy that involves the discontinuation or reduction of anticholinergic medications in patients where they are no longer clinically indicated.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:57:24.782Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of anticholinergic medication burden in patients at risk for anticholinergic-related adverse effects"}]},"trialDetails":[{"nctId":"NCT06562608","phase":"PHASE4","title":"Anticholinergic Deprescription in Schizophrenia","status":"RECRUITING","sponsor":"Deepak K. Sarpal, M.D.","startDate":"2025-02-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":105},{"nctId":"NCT04612166","phase":"NA","title":"Medication Empowerment and Deprescription for Safety (MEDS) Study","status":"UNKNOWN","sponsor":"University of Iowa","startDate":"2020-08-01","conditions":"Aging, Fall Injury","enrollment":398}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"No Anticholinergic Deprescription","genericName":"No Anticholinergic Deprescription","companyName":"Deepak K. Sarpal, M.D.","companyId":"deepak-k-sarpal-m-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a deprescribing strategy that involves the discontinuation or reduction of anticholinergic medications in patients where they are no longer clinically indicated. Used for Reduction of anticholinergic medication burden in patients with polypharmacy, Prevention of anticholinergic-related adverse effects in older adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}